

Resource Summary Report

Generated by [RRID](#) on Jul 31, 2026

IgG

RRID:AB_2738092

Type: Antibody

Proper Citation

BD Biosciences Cat# 563246, RRID:AB_2738092

Antibody Information

URL: http://antibodyregistry.org/AB_2738092

Proper Citation: BD Biosciences Cat# 563246, RRID:AB_2738092

Target Antigen: IgG

Host Organism: mouse

Clonality: monoclonal

Comments: Flow cytometry

Antibody Name: IgG

Description: This monoclonal targets IgG

Target Organism: human

Clone ID: G18-145

Antibody ID: AB_2738092

Vendor: BD Biosciences

Catalog Number: 563246

Record Creation Time: 20250820T034438+0000

Record Last Update: 20250820T170438+0000

Ratings and Alerts

No rating or validation information has been found for IgG.

No alerts have been found for IgG.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 14 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Bone B, et al. (2025) Distinct viral reservoirs and immune signatures in individuals on long-term antiretroviral therapy with perinatally acquired HIV-1. *Cell reports. Medicine*, 6(6), 102150.

Sutton HJ, et al. (2025) Simultaneous induction of multiple classes of broadly neutralizing antibody precursors by combination germline-targeting immunization in nonhuman primates. *Science immunology*, 10(112), eadu8878.

Madden PJ, et al. (2025) Diverse priming outcomes under conditions of very rare precursor B cells. *Immunity*, 58(4), 997.

Dyikanov D, et al. (2024) Comprehensive peripheral blood immunoprofiling reveals five immunotypes with immunotherapy response characteristics in patients with cancer. *Cancer cell*, 42(5), 759.

Shin OS, et al. (2024) Crimean-Congo hemorrhagic fever survivors elicit protective non-neutralizing antibodies that target 11 overlapping regions on glycoprotein GP38. *Cell reports*, 43(7), 114502.

Zhou P, et al. (2023) Broadly neutralizing anti-S2 antibodies protect against all three human betacoronaviruses that cause deadly disease. *Immunity*, 56(3), 669.

Zaitsev A, et al. (2022) Precise reconstruction of the TME using bulk RNA-seq and a machine learning algorithm trained on artificial transcriptomes. *Cancer cell*, 40(8), 879.

Lozano-Rodríguez R, et al. (2022) Cellular and humoral functional responses after BNT162b2 mRNA vaccination differ longitudinally between naive and subjects recovered from COVID-19. *Cell reports*, 38(2), 110235.

Rappazzo CG, et al. (2022) Potently neutralizing and protective anti-human metapneumovirus antibodies target diverse sites on the fusion glycoprotein. *Immunity*, 55(9), 1710.

Cotugno N, et al. (2021) Virological and immunological features of SARS-CoV-2-infected children who develop neutralizing antibodies. *Cell reports*, 34(11), 108852.

Cheng C, et al. (2020) Immune Monitoring Reveals Fusion Peptide Priming to Imprint Cross-Clade HIV-Neutralizing Responses with a Characteristic Early B Cell Signature. *Cell reports*, 32(5), 107981.

Shehata L, et al. (2019) Affinity Maturation Enhances Antibody Specificity but Compromises Conformational Stability. *Cell reports*, 28(13), 3300.

Rijal P, et al. (2019) Therapeutic Monoclonal Antibodies for Ebola Virus Infection Derived from Vaccinated Humans. *Cell reports*, 27(1), 172.

Kong R, et al. (2019) Antibody Lineages with Vaccine-Induced Antigen-Binding Hotspots Develop Broad HIV Neutralization. *Cell*, 178(3), 567.